Toray Develops Porous Fiber to Adsorb Pathogens of Intractable Diseases
Toray has developed a technology to precisely control the pore size of PMMA porous fibers, enabling the selective removal of disease-causing substances. The technology aims to offer new blood purification therapies for intractable diseases.
📋 Article Processing Timeline
- 📰 Published: March 26, 2026 at 23:59
- 🔍 Collected: March 28, 2026 at 21:59 (46h 0m after Published)
- 🤖 AI Analyzed: April 15, 2026 at 02:34 (412h 35m after Collected)
Toray Industries, Inc. has developed a technology to control the pore size of polymethyl methacrylate (PMMA) porous fibers in a range from a few nanometers to approximately 1,000 nanometers. This advancement allows for the selective adsorption of disease-causing substances, such as autoantibodies and lipoproteins, which are linked to intractable diseases like autoimmune disorders, cancer, and neurodegenerative diseases. Toray aims to commercialize this technology for both therapeutic blood purification and biopharmaceutical manufacturing applications.
FAQ
What is the primary benefit of this new technology?
It enables the selective adsorption and removal of large-molecular-weight disease-causing substances that were previously difficult to capture.